



References



References

- Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J:** Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer: Results of a large case-control study. *Carcinogenesis* 2008; 29: 93–99.
- Adams JS, Hewison M :** Update in vitamin D. *J Clin Endocrinol Metab* 2010; 95:471-8.
- Adorini A, Penna G.** Control of autoimmune diseases by the vitamin D endocrine system. *Nat Clin Pract Rheumatol* 2008; 4:404–12.
- Adorini L, Giarratana N, Penna G :** Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. *Semin Immunol* 2004;16: 127–134.
- Adorini L, Penna G :** Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. *Hum Immunol* 2009; 70: 345–352.
- Adorini L, Penna G, Giarratana N, Roncari A, Amuchastegui S, Daniel KC and Uskokovic M:** Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. *J Steroid Biochem Mol Biol* 2004;89-90: 437-441 .
- Adorini L:** Intervention in autoimmunity: the potential of vitamin D receptor agonists. *Cell Immunol* 2005;233: 115-124 .
- Adrian F. Gombart, Quang T. Luong and H. Philip Koeffler:** Vitamin D Compounds: Activity Against Microbes and Cancer. *Anticancer research* 2006; 26: 2531-2542 .
- Agarwal R, Acharya M, Tian J et al. :** Antiproteinuric effect of oral paricalcitol in chronic kidney disease. *Kidney Int* 2005; 68: 2823–2828.

Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T, Yamaguchi H, Hashizume S, Kato M, Yoshimura K, Yamamoto Y, Kato S, Matsumoto T : Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. *J Biol Chem* 2004 ;279:35798–35802 .

Alborzi P, Patel NA, Peterson C et al.: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. *Hypertension* 2008; 52: 249–255.

Andersen S, Tarnow L, Rossing P et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. *Kidney Int* 2000; 57: 601–606.

Anderson JL, May HT, Horne BD, et al.: Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. *Am J Cardiol* 2010;106:963-968 .

Andjelkovic Z, Vojinovic J, Pejnovic N et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. *Clin Exp Rheumatol* 1999;17:453–6.

Annemieke Verstuyf, Geert Carmeliet, Roger Bouillon and Chantal Mathieu: Vitamin D: a pleiotropic hormone . *Kidney International* 2010 ; 78, 140–145; doi:10.1038.

Armas LAG, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. *J Clin Endocrinol Metab* 2004; 89: 5387–5391.

Baeke F, van Etten E, Gysemans C et al.: Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. *Mol Aspects Med* 2008; 29: 376–387.

- Baranzini, S. E., N. W. Galwey, J. Wang, P. Khankhanian, R. Lindberg, D. Pelletier, W. Wu, B. M. Uitdehaag, L. Kappos, C.H. Polman, P. M. Matthews, S. L. Hauser, R. A. Gibson, J. R. Oksenberg, and M. R. Barnes** :Pathway and networkbased analysis of genome-wide association studies in multiple sclerosis. *Hum Mol Genet* 2009;18:2078-2090.
- Benn BS, Ajibade D, Porta A et al.** : Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin- D9k. *Endocrinology* 2008; 149: 3196–3205.
- Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL**: Antiproliferative effects of 1, 25-dihydroxyvitamin D3 and vitamin D analogs on tumor-derived endothelial cells. *Endocrinology* 2002; 143: 2508–2514.
- Bertone-Johnson ER, Chen WY, Holick MF et al.**: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 1991–1997.
- Bertrand Carlander, Anne Marie Puech-Cathala, Isabelle Jaussent, et al.** : Low Vitamin D in Narcolepsy with Cataplexy . *PLoS One*. 2011; 6(5): e20433.
- Bianco SD, Peng JB, Takanaga H et al.**: Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. *J Bone Miner Res* 2007; 22: 274–285.
- Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR Karumanchi SA, Thadhani R, Kang PM**: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. *Proc Natl Acad Sci U S A* 2007; 104: 16810–16815.

References

- Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E, McCauliffe D, Wozniacka A :** Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters . *Lupus* 2012; 21(5):477-84.
- Bonizzi G, Karin M:** The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol* 2004; 25: 280–288.
- Bouillon R :** Vitamin D as potential baseline therapy for blood pressure control. *Am J Hypertens* 2009; 22: 816.
- Bouillon R, Carmeliet G, Verlinden L:** Vitamin D and human health: lessons from vitamin D receptor null mice. *Endocr. Rev.*2008; 29, 726–776 .
- Brewer LC, Michos ED, Reis JP:** Vitamin D in atherosclerosis, vascular disease, and endothelial function. *Curr Drug Targets* 2011;12:54-60.
- Brewster UC, Perazella MA:** The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. *Am J Med* 2004; 116: 263–272.
- Buell JS, Dawson-Hughes B.** Vitamin D and neurocognitive dysfunction: preventing “D”ecline? *Mol Aspects Med* 2008;29:415 22.
- C. R. Scherzer, A. C. Eklund, L. J. Morse et al. :**Molecular markers of early Parkinson’s disease based on gene expression in blood . *National Academy of Sciences USA* 2007; vol. 104, no. 3, pp. 955–960.
- Cannell, J. J. & Hollis, B. w.:** Use of vitamin D in clinical practice. *Altern Med Rev* 2008; 13, 6–20 .
- Cantorna MT :** Vitamin D and multiple sclerosis: an update. *Nutr Rev* 2008;66: S135–S138.

References

- Carey RM, Siragy HM :** The intrarenal renin-angiotensin system and diabetic nephropathy. *Trends Endocrinol Metab* 2003; 14:274–281.
- Cavalier E, Delanaye P, Souberbielle JC, Radermecker RP:** Vitamin D and type 2 diabetes mellitus: Where do we stand? *Diabetes Metab* 2011; 37:265-272.
- Chonchol M, Scragg R :** 25-Hydroxyvitamin D, insulinresistance, and kidney function in the Third National Health and Nutrition Examination Survey. *Kidney Int* 2007; 71:134–139 .
- Colston KW :** Vitamin D and breast cancer risk. *Best Pract Res Clin Endocrinol Metab* 2008; 22: 587–599.
- Correale J, Ysrraelit MC, Gaitán MI:** Immunomodulatory effects of Vitamin D in multiple sclerosis. *Brain* 2009; 132(Pt 5):1146-60 .
- Correale, J., M. C. Ysrraelit, and M. I. Gaitan :** Genderdifferences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. *J Immunol* 2010; 185:4948-4958.
- Cutolo M, Otsa K :** Vitamin D, immunity and lupus. *Lupus* 2008;17:6–10.
- Cutolo M, Otsa K, Laas K et al. :** Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. *Clin Exp Rheumatol* 2006; 24:702–4.
- Cutolo M.** Vitamin D and autoimmune rheumatic diseases. *Rheumatology* 2009; 48: 210-212.
- Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, et al.** Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. *J Clin Invest.* 2010;120:713-9.

D. W. Eyles, S. Smith, R. Kinobe, M. Hewison, and J. J. McGrath:

Distribution of the Vitamin D receptor and 1 α -hydroxylase in human brain.
Journal of Chemical Neuroanatomy 2005; vol. 29, no. 1, pp. 21–30 .

Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of
hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment.
Neurology 2009;73:1333-4.

Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. *Lancet*.
2007;369:499-511.

Dauvilliers Y, Maret S, Bassetti C, Carlander B, Billiard M, et al.:A
monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1.
Neurology 2004; 62:2137-8.

Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, et al. Age at
onset of narcolepsy in two large populations of patients in France and
Quebec. *Neurology* 2001;57:2029-2033.

De Boer IH, Ioannou GN, Kestenbaum B et al.: 25-Hydroxyvitamin D levels
and albuminuria in the Third National Health and Nutrition Examination
Survey (NHANES III). *Am J Kidney Dis* 2007; 50: 69–77.

**De Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick
DS :** 25-hydroxyvitamin D levels inversely associate with risk for
developing coronary artery calcification. *J Am Soc Nephrol* 2009;
20:1805–1812 .

Deb DK, Chen Y, Zhang Z et al.: 1,25-Dihydroxyvitamin D3 suppresses high
glucose-induced angiotensinogen expression in kidney cells by blocking
the NF-kB pathway. *Am J Physiol Renal Physiol* 2009; 296: F1212–
F1218.

References

- Deeb KK, Trump DL, Johnson C :** Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. *Nat Rev Cancer* 2007; 7:684–700.
- Drechsler C, Pilz S, Obermayer-Pietsch B, et al. :** Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. *Eur Heart J* 2010; 31:2253-2261.
- Dusso AS, Tokumoto M.** Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. *Kidney Int* 2011;79:715-729 .
- Dusso, AS, Brown, A. J. & Slatopolsky, e.** Vitamin D. *Am. J. Physiol. Renal Physiol.* 2005; 289, F8–F28.
- Ebers, G. C. :** Environmental factors and multiple sclerosis. *Lancet neurology* 2009; 7:268-277.
- Ford ES, Ajani UA, McGuire LC, Liu S :** Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. *Diabetes Care* 2005; 28:1228–123061.
- Friedrich M, Reichrath J, Chen TC, Tanpricha V, Gherson I, Tilgen W, Schmidt W & Holick MF:** Expression of 25-hydroxyvitamin D3-1 α -hydroxylase in breast tissue. In *Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects* 2000 ; 189–192 .
- Fujita H, Sugimoto K, Inatomi S et al.:** Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca²⁺ absorption between enterocytes. *Mol Biol Cell* 2008; 19: 1912–1921.
- Gardiner EM, Baldock PA, Thomas GP et al. :** Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. *FASEB J* 2000; 14: 1908–1916.

References

- Gardner DG, Glenn D, Nei W et al.:** Cardiomyocyte-specific vitamin D receptor gene knockout causes cardiac hypertrophy. Abstract at the 14th workshop on vitamin D, 2009, Brugge, Belgium.
- Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ:** Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. *Am J Nephrol* 2004; 24: 503–510.
- Gorham ED, Garland CF, Garland FC et al.:** Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. *Am J Prev Med* 2007; 32: 210–216
- Griffin MD and Kumar R:** Effects of 1 α ,25(OH) $_2$ D $_3$ and its analogs on dendritic cell function. *J Cell Biochem* 2003; 88: 323–326
- Guijarro C, Egido J :** Transcription factor-kappa B (NF-kappa B) and renal disease. *Kidney Int* 2001; 59: 415–424.
- H. Kaur, K. C. Donaghue, A. K. Chan et al.,** “Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes,” *Diabetes Care*, vol. 34, no. 6, pp. 1400–1402, 2011.
- Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, et al.** Narcolepsy is strongly associated with the T-cell receptor alpha locus. *Nat Genet.* 2009;41:708-11.
- Hamza RT, Awwad KS, Ali MK, Hamed AI :** Reduced serum concentration of 25-hydroxy vitamin D in Egyptian patients with SLE :Relation to disease activity. *Med Sci Monit.* 2011; 17(12):CR711-8.
- Hathcock, J. N., shao, A., vieth, r. & Heaney, r.:** Risk assessment for vitamin D. *Am. J. Clin. Nutr.* 2007; 85 : 6–18 .

- Haussler MR, Whitfield GK, Haussler CA et al. :** The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J. Bone Miner Res* 1998; 13: 325–349.
- Heaney RP :** Vitamin D in health and disease. *Clin J Am Soc Nephrol* 2008;3:1535-1541.
- Hewison M, Barker S, Brennan A, Nathan J, Katz DR and O'Riordan JL:** Autocrine regulation of 1,25dihydroxycholecalciferol metabolism in myelomonocytic cells. *Immunology* 1989; 68: 247-252. Higher 25-hydroxyvitamin D is associated with lower relapse
- Hoenderop JG, van Leeuwen JP, van der Eerden BC et al.:** Renal Ca²⁺ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. *J Clin Invest* 2003; 112: 1906–1914.
- Hoffmann S, Podlich D, Hahnel B et al.:** Angiotensin II type 1 receptor over expression in podocyte induces glomerulosclerosis in transgenic rats. *J Am Soc Nephrol* 2004; 15: 1475–1487.
- Holick MF :** Vitamin D deficiency. *N Engl J Med* 2007; 357: 266–281.
- Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A , Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD:** Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab* 2008; 93: 677–681.
- Holick MF:** Diabetes and Vitamin D. *Vitamin D health.org* ,2008
- Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, et al.** Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. *Nat Genet.* 2010;42:786-9.

- Hyppönen E, Lahti A, Reunanen A, Järvelin M-J, Virtanen SM:** Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. *Lancet* 2001; 358: 1500–1503.
- Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V :** Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008;87:136–141.
- Kamen DL, Aranow C :** The link between vitamin D deficiency and systemic lupus erythematosus. *Curr Rheumatol Rep.* 2008 ;10(4):273-80.
- KDIGO** Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease Related Mineral and Bone Disorders (CKD-MBD). Available at: http://www.kdigo.org/clinical_practice_guidelines_1.php. Accessed March 18, 2009.
- Khanh Lu'o'ng and Lan Nguyen :** Role of Vitamin D in Parkinson's Disease. *ISRN Neurology* 2012; Article ID 134289 doi:10.5402/2012/134289
- Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ :** Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). *Am J Cardiol* 2008; 102:1540–1544
- Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK:** Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. *Nephron Clin Pract* 2006; 102: c21–c29.

- Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dank K, Szekanecz Z, Langevitz P, Shoenfeld Y:** Vitamin D and autoimmune thyroid diseases. *Cell Mol Immunol* 2011 8(3):243-7 .
- Knight :**Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. *PLoS genetics* 2009; 5:e1000369.
- Koch, M., E. Kingwell, P. Rieckmann, and H. Tremlett :** The natural history of secondary progressive multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry* 2010; 81:1039-1043.
- Kovesdy CP, Kalantar-Zadeh K :** Vitamin D receptor activation and survival in chronic kidney disease. *Kidney Int* 2008; 73: 1355–1363.
- LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Graves KL, Moe SM:** Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. *Am J Kidney Dis* 2005; 45: 1026–1033.
- Lappe JM, Travers-Gustafson D, Davies KM et al.:** Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr* 2007; 85: 1586–1591.
- Lehmann B :** The vitamin D3 pathway in human skin and its role for regulation of biological processes. *Photochem Photobiol* 2005; 81:1246–1251.
- Levin A, Bakris GL, Molitch M et al.:** Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int* 2007; 71: 31–38.

References

- Levin A, Guiterrez W, Andress D, Wolf M:** Deficiencies of Vitamin D are associated with inflammation and albuminuria. *J Am Soc Nephrol* 2007; 18: 527A .
- Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP :** 1, 25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;110:229–2 .
- Li YC, Qiao G, Uskokovic M :** Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. *J Steroid Biochem Mol Biol* 2004; 89–90: 387–392.
- Lieben L, Masuyama R, Moermans K :** Intestinal-Specific Vitamin D receptor null mice maintain normal calcemia but display severe bone loss. *J Bone Miner Res* 2008; 23: S104.
- Liss Y, Frishman WH :** Vitamin D: a cardioprotective agent . *Cardiol Rev.* 2012 ;20(1):38-44 .
- Liu PT, Stenger S, Li H :** Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006; 311: 1770–1773.
- M. L. Evatt, M. R. DeLong, M. Kumari, P. Auinger, M.P. McDermott, and V. Tangpricha :** High prevalence of hypovitaminosis D status in patients with early Parkinson disease . *Neurology* 2011; vol. 68, no. 3, pp. 314–319.
- M. W. Butler, A. Burt, T. L. Edwards :** Vitamin D receptor gene as a candidate gene for Parkinson disease. *Annals of Human Genetics* 2011; vol. 75, no. 2, pp. 201–210.
- Macdonald HM, Mavroeidi A, Fraser WD :** Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal

women living at northerly latitudes: a major cause for concern?
Osteoporos Int 2011;22:2461-2472 .

Manraj Johal and Adeera Levin : Vitamin D and Parathyroid Hormone in
General Populations: Understandings in 2009 and Applications to
Chronic Kidney Disease .*Clin J Am Soc Nephrol* 2009; 4: 1508–1514 .

Margolis KL, Ray RM, Van HL: Effect of calcium and vitamin D
supplementation on blood pressure: the Women's Health Initiative
Randomized Trial. *Hypertension* 2008; 52: 847–855.

**Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B,
Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ,
Rainbow SJ, Berry JL, Griffiths CJ:** A single dose of vitamin D
enhances immunity to mycobacteria. *Am J Respir Crit Care Med* 2007;
176: 208–213.

**Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A,
Levine B, Mehrotra R, Norris K** : Prevalence of cardiovascular risk
factor and the serum levels of 25 hydroxyvitamin D in the United States:
data from the Third National Health and Nutrition Examination Survey.
Arch Intern Med 2007; 167:1159–1165.

Masuyama R, Stockmans I, Torrekens S et al.: Vitamin D receptor in
chondrocytes promotes osteoclastogenesis and regulates FGF23
production in osteoblasts. *J Clin Invest* 2006; 116: 3150–3159.

Mathieu C, Gysemans C, Giuliatti A et al.: Vitamin D and diabetes.
Diabetologia 2005; 48: 1247–1257.

References

- Matias PJ, Jorge C, Ferreira C, et al.:** Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. *Clin J Am Soc Nephrol* 2010;5:905-911.
- Medici, D. et al.:** FGF 23 Klotho signaling stimulates proliferation and prevents vitamin D induced apoptosis. *J Cell Biol* 2008;. 182, 459–465 .
- Medioni J, Deplanque G, Maurina T et al.:** Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. *J Clin Oncol* 2009;155: 5151.
- Meems LM, van der Harst P, van Gilst WH, de Boer RA :** Vitamin D biology in heart failure: molecular mechanisms and systematic review. *Curr Drug Targets* 2011;12:29-41 .
- Meir T, Levi R, Lieben L et al .:** Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the VDR in parathyroid physiology. *Am J Physiol Renal Physiol* 2009; 297:F1192–F1198
- Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Iowa :** Women’s Health Study. *Arthritis Rheum* 2004; 50:72–7.
- Mitri J, Dawson-Hughes B, Hu FB, Pittas AG:** Effects of vitamin D and calcium supplementation on pancreatic B cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. *Am J Clin Nutr* 2011; 94(2):486-94 .

References

- MJ, Siscovick DS** : 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. *J Am Soc Nephrol* 2009; 20:1805–1812 .
- Mowry, E. M., L. B. Krupp, M. Milazzo, D. Chabas, J. B. Strober, A. L. Belman, J. C. McDonald, J. R. Oksenberg, P. Bacchetti, and E. Wauban** : Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. *Ann Neurol* 2010; 67:618-624.
- Muller DN, Luft FC** : Direct renin inhibition with aliskiren in hypertension and target organ damage. *Clin J Am Soc Nephrol* 2006; 1: 221–228.
- Munger KL, Levin LI, Hollis BW et al.**: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA* 2006; 296: 2832–2838.
- Munger KL, Levin LI, Hollis, BW, Howard NS, Ascheino A**: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA* 2006; 296:2832-2838 .
- N. Tokuda and R. B. Levy: 1, 25-Dihydroxyvitamin D3 stimulates** phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. *Society for Experimental Biology and Medicine* 1996: vol. 211, no. 3, pp. 244–250.
- Nagpal S, Na S, Rathnachalam R** : Noncalcemic actions of vitamin D receptor ligands. *Endocr Rev* 2005; 26: 662–687.
- Naja RP, Dardenne O, Arabian A et al.**: Chondrocyte-specific modulation of CYP27B1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. *Endocrinology* 2009;150: 4024–4032.

- Narvaez CJ, Zinser G & Welsh JE:** Functions of 1 α , 25-dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer. *Steroids* 2001; **66** 301–308.
- Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU:** 1, 25(OH) 2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. *J Steroid Biochem Mol Biol* 2007; 103: 533– 537.
- Norman, P. e. & Powell, J. T.:** vitamin D, shedding light on the development of disease in peripheral arteries. *Arterioscler. Thromb. Vasc. Biol.* 2005; 25: 39–46 .
- Nursyam EW, Amin Z, Rumende CM:** The effect of vitamin D as supplementary treatment in patients with moderately advanced tuberculous lesion. *Acta Med Indones* 2006; 38: 3–5.
- Nykjaer A, Dragun D, Walther D et al.:** An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. *Cell* 1999;96: 507–515.
- Oudshoorn C, Mattace-Raso FU, van der Velde N, Colin EM, van der Cammen TJ.:** Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. *Dement Geriatr Cogn Disord* 2008;25:539– 43.
- Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, Rutgeerts O, Saint-Arnaud R, Bouillon R and Mathieu C:** Identification and immune regulation of 25- hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. *Clin Exp Immunol* 2000; 120: 139-146 .

P. Knekt, A. Kilkkinen, H. Rissanen, J. Marniemi, K. S    ksj  arvi, and M.

Heli  ovaara: Serum vitamin D and the risk of Parkinson disease.

Neurology 2010; vol. 67, no.7, pp. 808–811 .

P. L.McGeer, S. Itagaki, B. E. Boyes, and E. G.McGeer : Reactive microglia

are positive forHLA-DR in the substantia nigra of Parkinson’s and

Alzheimer’s disease brains . *Neurology* 1988:vol. 38, no. 8, pp. 1285–

1291.

Palomer X, Gonza  lez-Clemente JM, Blanco-Vaca F, Mauricio D.: Role of

vitamin D in the pathogenesis of type 2 diabetes mellitus. *Diabetes Obes*

Metab 2008;10:185–97.

Parving HH, Persson F, Lewis JB et al.: Aliskiren combined with losartan in

type 2 diabetes and nephropathy. *N Engl J Med* 2008; 358:2433–2446.

Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D : Association

between serum vitamin D metabolite levels and disease activity in

patients with early inflammatory polyarthritis. *Arthritis Rheum* 2007;

56:2143–2149.

Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D. Association

between serum vitamin D metabolite levels and disease activity in

patients with early inflammatory polyarthritis. *Arthritis Rheum*

2007;56:2143–9.

Patr  cia Matias :Vitamin D and cardiovascular disease in CKD patients. *CIN*

2011; 2-6 .

Peterlik, M & Cross, H. S. Vitamin D and calcium deficits predispose for

multiple chronic diseases. *Eur J Clin Invest* 2005; 35, 290–304 .

- Pierrot-Deseilligny C, Souberbielle JC.** Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? *Brain*.
- Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S :**Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. *Am J Kidney Dis* 2011;58:374-382.
- Pilz S, Tomaschitz A, Drechsler C, de Boer RA :** Vitamin D deficiency and heart disease. *Kidney Int Suppl* 2011;1:11-115.
- Pittas AG, Dawson-Hughes B, Li T, et al.:** Vitamin D and calcium intake in relation to type 2 diabetes in women. *Diabetes Care* 2006;29:650-56.
- Pittas AG, Lau J, Hu FB, Dawson-Hughes B. :**Therole of vitamin D andcalcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007;92:2017–29.
- Ramagopalan, S. V., N. J. Maugeri, L. Handunnetthi, M. R. Lincoln, S. M. Orton, D. A. Dymment, G. C. Deluca, B. M.Herrera, M. J. Chao, A. D. Sadovnick, G. C. Ebers, and J. C.:**risk in MS. *Annals of neurology* in press 2010 .
- Ravani P, Malberti F, Tripepi G et al.:** Vitamin D levels and patient outcome in chronic kidney disease. *Kidney Int* 2009; 75: 88–95.
- Reichel H, Koeffler HP, Barbers R and Norman AW:** Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. *J Clin Endocrinol Metab* 1987; 65: 1201-1209.
- Renne J, Werfel T, Wittmann M :** High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus. *Br J Dermatol* 2008; 159: 479-511.

References

Ruster C, Wolf G : Renin-angiotensin-aldosterone system and progression of renal disease. *J Am Soc Nephrol* 2006; 17: 2985–2991.

Ruster C, Wolf G.: Renin-angiotensin-aldosterone system and progression of renal disease. *J Am Soc Nephrol* 2006; 17: 2985–2991.

Schmitz KJ, Skinner HG, Bautista LE et al.: Association of 25-hydroxyvitaminD with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. *Am J Hypertens* 2009; 22:867–870.

Scragg R, Sowers MF, Bell C: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. *Diabetes Care* 2004; 27: 2813–2818.

Shoben AB, Rudser KD, de Boer IH et al.: Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD. *J Am Soc Nephrol* 2008; 19: 1613–1619.

Sigmundsdottir H, Pan J, Debes GF et al.: DCs metabolize sunlightinduced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. *Nat Immunol* 2007; 8: 285–293.

Simpson, S., B. Taylor, L. Blizzard, A.-L. Ponsonby, F. Pittas, H. Tremlett, T. Dwyer, P. Gies, and I. A. van der Mei :Smolders, J., E. Peelen, M. Thewissen, P. Menheere, J. W.Cohen Tervaert, R. Hupperts, and J. Damoiseaux: The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. *Autoimmun Rev* 2009; 8: 621-626.

- Sloka S, Grant M, Newhook L.** :The geospatial relation between UV solar radiation and type 1 diabetes in Newfoundland. *Acta Diabetol* 2009; epub ahead of print.
- Sooy K, Sabbagh Y, Demay MB:** Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. *J Cell Biochem* 2005; 94: 81–87.
- Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, Holick MF:** Vitamin D and cancer. *Anticancer Res* 2006; 26: 2515–2524.
- Stephen G. Rostand, David G. Warnock:** The role for vitamin D in multiple organ systems and physiologic and molecular processes. *Clin J Am Soc Nephrol* 2008; 3: 1534, doi: 10.2215/CJN.01130308.
- Sun J, Kong J, Duan Y et al.:** Increased NF- κ B activity in fibroblasts lacking the vitamin D receptor. *Am J Physiol Endocrinol Metab* 2006; 291: E315–E322.
- Sun X, Zemel MB :** Calcium and 1, 25-dihydroxyvitamin D3 regulation of adipokine expression. *Obesity (Silver Spring)* 2007;15:340–348 .
- Swami S, Krishnan AV & Feldman D:** 1 α ,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen action in MCF-7 human breast cancer cells. *Clinical Cancer Research* 2000; 6 3371–3379.
- Szeles L, Keresztes G, Torocsik D et al.:** 1,25-Dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. *J Immunol* 2009; 182:2074–2083.
- T. H. J. Burne, J. J. McGrath, D. W. Eyles, and A. Mackay- Sim :**Behavioural characterization of Vitamin D receptor knockout mice .*Behavioural Brain Research* 2005; vol. 157, no. 2, pp. 299–308 .

- Takiishi T, Hysemans C, Bouillon R, et al.:** Vitamin D and diabetes. *Endocrinol Metab Clin North Am* 2010; 39:419-446 .
- Teng M, Wolf M, Lowrie E et al.:** Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *N Engl J Med* 2003;349: 446–456.
- Teng M, Wolf M, Ofsthun MN et al.:** Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 2005; 16: 1115–1125.
- Tentori F, Hunt WC, Stidley CA et al.:** Mortality risk among hemodialysis patients receiving different vitamin D analogs. *Kidney Int* 2006; 70:1858–1865.
- Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ :** Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *Q J Med* 2002; 95:787–796.
- Travis RC, Crowe FL, Allen NE et al.:** Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Epidemiol* 2009; 169:1223–1232.
- U. Fiszer, E. Mix, S. Fredrikson, V. Kostulas, and H. Link :** Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood . *Acta Neurologica Scandinavica* 1994; vol. 90, no. 3, pp. 160–166.
- Van Cromphaut SJ, Dewerchin M, Hoenderop JG et al. :** Duodenal calcium absorption in vitamin D receptor-knockout mice: functional

and molecular aspects. Proc Natl Acad Sci USA 2001; 98: 13324–13329.

Van der Wielen RP, Lowik MR, van den BH et al.: Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207–210.

Verlinden L, Eelen G, Van HR et al.: 1 α ,25-Dihydroxyvitamin D₃-induced down-regulation of the checkpoint proteins, Chk1 and Claspin, is mediated by the pocket proteins p107 and p130. J Steroid Biochem Mol Biol 2007; 103: 411–415.

Wactawski-Wende J, Kotchen JM, Anderson GL et al.: Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684–696.

Wang X, Gocek E, Liu CG et al.: MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D₃. Cell Cycle 2009; 8: 736–741.

Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, Sun XJ, Li YC : Involvement of the vitamin D receptor in energymetabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 2009; 296:E820–E828

Wu-Wong JR, Nakane M, Ma J : Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res 2007; 44:11–18 .

References

- Xue Y, Fleet JC.** : Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. *Gastroenterology* 2009; 136:1317–1327.
- Yan Chun Li** : *Kidney International* (2010) 78, 134–139; doi:10.1038/ki.2009.175; published online 2009 .
- Yin L, Grandi N, Raum E et al.:** Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. *Aliment Pharmacol Ther* 2009; 30:113–125.
- Yu S, Bruce D, Froicu M et al.:** Failure of T cell homing, reduced CD4/CD8alpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. *Proc Natl Acad Sci USA* 2008; 105: 20834–20839.
- Zhang Z, Sun L, Wang Y et al.:** Renoprotective role of the vitamin D receptor in diabetic nephropathy. *Kidney Int* 2008; 73: 163–171.
- Zhang Z, Zhang Y, Ning G et al.:** Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. *Proc Natl Acad Sci USA* 2008;105: 15896–15901.
- Zhou W, Suk R, Liu G, et al.:** Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 2005;14:2303-2309.